[1]郑宁宁,薛绍鸥,李娟,等.骨肉瘤组织卵巢肿瘤含域蛋白酶-2和胶质细胞系源性神经营养因子受体1表达与临床病理特征及预后的关系[J].中国中医骨伤科杂志,2023,31(08):33-37.[doi:10.20085/j.cnki.issn1005-0205.230807 ]
　ZHENG Ningning,XUE Shaoou,LI Juan,et al.Expression of Ovarian Tumor Domain-Containing Protease-2 and Glial Cell Line-Derived Neurotrophic Factor Receptor 1 in Osteosarcoma and Their Relationship with Cinicopathological Characteristics and Prognosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2023,31(08):33-37.[doi:10.20085/j.cnki.issn1005-0205.230807 ]
点击复制

骨肉瘤组织卵巢肿瘤含域蛋白酶-2和胶质细胞系源性神经营养因子受体1表达与临床病理特征及预后的关系()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第31卷
期数:
2023年08期
页码:
33-37
栏目:
临床研究
出版日期:
2023-08-15

文章信息/Info

Title:
Expression of Ovarian Tumor Domain-Containing Protease-2 and Glial Cell Line-Derived Neurotrophic Factor Receptor 1 in Osteosarcoma and Their Relationship with Cinicopathological Characteristics and Prognosis
文章编号:
1005-0205(2023)08-0033-05
作者:
郑宁宁1; 薛绍鸥2; 李娟2; 王海梅2; 姜秀贞3; 李书迪4; 胡秀茹5
1河北省沧州中西医结合医院骨科(河北 沧州,061000)
2河北省沧州中西医结合医院护理部
3河北省沧州中西医结合医院乳腺外科
4河北省沧州中西医结合医院心理科
5河北省沧州中西医结合医院放化疗一科
Author(s):
ZHENG Ningning1; XUE Shaoou2; LI Juan2; WANG Haimei2; JIANG Xiuzhen3; LI Shudi4; HU Xiuru5
1Department of Orthopaedics,Cangzhou Hospital of Integrated Chinese and Western medicine,Cangzhou 061000,Hebei China; 2Department of Nursing,Cangzhou Hospital of Integrated Chinese and Western Medicine in Hebei Province,Cangzhou 061000,Hebei China; 3Department of Breast Surgery,Cangzhou Hospital of Integrated Chinese and Western Medicine in Hebei Province,Cangzhou 061000,Hebei China;...
关键词:
骨肉瘤;  卵巢肿瘤含域蛋白酶-2;  胶质细胞系源性神经营养因子受体1;  病理特征;  预后
Keywords:
osteosarcoma;  ovarian tumor domain-containing protease-2;  glial cell line-derived neurotrophic factor receptor 1;  pathological features;  prognosis
分类号:
R738.1
DOI:
10.20085/j.cnki.issn1005-0205.230807
文献标志码:
A
摘要:
目的:观察骨肉瘤组织中卵巢肿瘤含域蛋白酶-2(YOD1)和胶质细胞系源性神经营养因子受体1(GFRA1)表达情况,并探讨二者表达与病理特征及预后的关系。方法:收集2021年2月至2022年2月130例骨肉瘤患者骨肉瘤组织标本和瘤旁组织(距离肿瘤边缘大于5 cm)标本及临床资料,根据患者1年内死亡情况分为死亡组(40例)和生存组(90例)。采用免疫组织化学法检测组织YOD1和GFRA1表达水平,多因素Cox回归分析骨肉瘤患者预后的影响因素。结果:与瘤旁组织相比,骨肉瘤组织中YOD1阳性率和GFRA1阳性率显著较高,差异有统计学意义(P<0.05)。肿瘤最大径≥3 cm、临床分期为Ⅱb～Ⅲ期、有软组织浸润、有远处转移、低分化的骨肉瘤患者YOD1阳性率和GFRA1阳性率高于肿瘤最大径<3 cm、临床分期为Ⅰ～Ⅱa期、无软组织浸润、无远处转移、中/高分化的骨肉瘤患者,差异有统计学意义(P<0.05)。与生存组相比,死亡组中YOD1阳性率和GFRA1阳性率显著较高,差异有统计学意义(P<0.05)。YOD1、GFRA1及软组织浸润是骨肉瘤患者1年内死亡的独立危险因素,差异有统计学意义(P<0.05)。结论:YOD1和GFRA1在骨肉瘤组织中高表达,且与肿瘤最大径、临床分期、软组织浸润、远处转移、分化程度及预后有关。
Abstract:
Objective:To observe the expressions of ovarian tumor domain-containing protease-2(YOD1)and glial cell line-derived neurotrophic factor receptor 1(GFRA1)in osteosarcoma tissues,and to explore the relationship between their expressions and pathological characteristics and prognosis.Methods:The osteosarcoma tissue specimens and paratumor tissue(more than 5 cm from the tumor edge)specimens and clinical data of 130 patients with osteosarcoma from February 2021 to February 2022 were collected,the patients were divided into death group(40 cases)and survival group(90 cases)according to the death situation within 1 year.The expression levels of YOD1 and GFRA1 in tissues were detected by immunohistochemistry,and the prognostic factors of prognosis of patients with osteosarcoma were analyzed by multivariate Cox regression analysis.Results:The positive rates of YOD1 and GFRA1 in osteosarcoma tissue were obviously higher compared with adjacent tissue(P<0.05).The positive rates of YOD1 and GFRA1 in osteosarcoma patients with tumor maximum diameter ≥3 cm,clinical stage of stage Ⅱb-Ⅲ,soft tissue infiltration,distant metastasis,and poor differentiation were higher than those in patients with tumor maximum diameter <3 cm,clinical stage of stage Ⅰ-Ⅱa,no soft tissue infiltration,no distant metastasis,moderate/well differentiation(P<0.05).The positive rates of YOD1 and GFRA1 in the death group were significantly higher compared with the survival group(P<0.05).YOD1,GFRA1,and soft tissue infiltration were independent risk factors for 1-year death in patients with osteosarcoma(P<0.05).Conclusion:YOD1 and GFRA1 are highly expressed in osteosarcoma tissues,and are related to the maximum tumor diameter,clinical stage,soft tissue infiltration,distant metastasis,degree of differentiation and prognosis.

参考文献/References:

[1] SHOAIB Z,FAN T M,IRUDAYARAJ J M K.Osteosarcoma mechanobiology and therapeutic targets[J].Br J Pharmacol,2022,179(2):201-217.
[2] 秦桂福,吴琪,宋玉,等.徐长卿丹皮酚联合顺铂对骨肉瘤细胞迁移和凋亡及相关蛋白表达的影响[J].中国中医骨伤科杂志,2021,29(9):10-15.
[3] LEI T,QIAN H,LEI P,et al.Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma[J].Cancer Sci,2021,112(11):4785-4798.
[4] GONG M,LIU H,SUN N,et al.Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo[J].Nanomedicine(Lond),2020,15(7):711-723.
[5] KIM M,KIM D J.GFRA1:a novel molecular target for the prevention of osteosarcoma chemoresistance[J].Int J Mol Sci,2018,19(4):1078-1091.
[6] 中国医师协会骨科医师分会,骨肿瘤专业委员会.骨肉瘤临床循证诊疗指南[J].中华骨与关节外科杂志,2018,11(4):288-301.
[7] WANG P H,CHEN C M,CHEN C F,et al.Comparison of recycled autograft versus allograft in osteosarcoma with pathological fracture[J].Int Orthop,2021,45(8):2149-2158.
[8] LIU W,XIE X,QI Y,et al.Exploration of immune-related gene expression in osteosarcoma and association with outcomes[J].JAMA Netw Open,2021,4(8):1-11.
[9] SURI M,SONI N,OKPALEKE N,et al.A deep dive into the newest avenues of immunotherapy for pediatric osteosarcoma:a systematic review[J].Cureus,2021,13(9):1-14.
[10] LIU L,ZHANG X,LI C,et al.The value of Angipoietin-2 as a biomarker for the prognosis of osteosarcoma:a protocol for systematic review and meta-analysis[J].Medicine(Baltimore),2021,100(32):1-5.
[11] 黄晔,赖蔚菁,黄如,等.LncRNA OCPAT1通过调控miR-320d/YOD1信号通路促进卵巢癌的发生及发展[J].中国现代医生,2021,59(33):41-44.
[12] ZHANG Z,ZHAO W,LI Y,et al.YOD1 serves as a potential prognostic biomarker for pancreatic cancer[J].Cancer Cell Int,2022,22(1):203-228.
[13] YAN R,JIN S,LIU H,et al.Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome[J].Biochem Biophys Res Commun,2021,543(1):56-64.
[14] ZHANG J,RAO D,MA H,et al.LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p/GFRA1 axis[J].Open Life Sci,2020,15(1):871-883.
[15] HE P,XU Y Q,WANG Z J,et al.LncRNA LINC00210 regulated radiosensitivity of osteosarcoma cells via miR-342-3p/GFRA1 axis[J].J Clin Lab Anal,2020,34(12):1-9.

备注/Memo

备注/Memo:
基金项目:2022年度河北医学科技计划项目(20220679)
更新日期/Last Update: 2023-08-01